2026-04-11T11:08:25Z https://pub.unibl.org/oai

oai:pub.unibl.org:40237 2024-06-12T14:22:23Z

3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study /unibl/author/Josef S Smolen /unibl/author/Jung Yoon Choe /unibl/author/Nenad Prodanović /unibl/author/Y.H, Rho 2017 Academic Article text 10 10 /unibl/sci/idNaucniRad:25128 ANNALS OF THE RHEUMATIC DISEASES 0003-4967 ANNALS OF THE RHEUMATIC DISEASES 0003-4967 J. Smolen, J. Choe, N. Prodanović, Y. Rho, 3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2017 https://pub.unibl.org/s/cir/item/40237